Your session is about to expire
← Back to Search
Radioactive Drug Therapy for Prostate Cancer
Study Summary
This trial studies how well a radioactive drug can treat prostate cancer that has spread to other places in the body. It may carry radiation directly to tumor cells, without damaging normal cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have another cancer that won't affect this treatment's safety or results.My heart condition does not severely limit my daily activities.I am HIV-positive, on treatment, and my viral load is undetectable.My blood, kidney, and liver functions are all within normal ranges.My prostate cancer has spread and shows neuroendocrine features.Your disease is getting worse according to specific medical criteria.I have not used long-acting somatostatin analogs in the last 4 weeks or short-acting ones in the last 24 hours, unless to control carcinoid syndrome.I am on medication to keep my testosterone low, or I've had surgery to remove my testicles.Your high blood pressure is not well controlled, based on specific blood pressure numbers at the screening.I will have a special scan and must test positive to continue with my treatment.I am not using any other cancer treatments.I am allergic to medications similar to Lutetium Lu 177 dotatate.I haven't had any major heart problems in the last 6 months.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.I have chronic hepatitis B but it's under control with treatment.I had hepatitis C but am now cured or have no detectable virus while on treatment.My treated brain metastases are not getting worse according to recent scans.
- Group 1: Treatment (lutetium Lu 177 dotatate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has lutetium Lu 177 dotatate achieved regulatory approval from the FDA?
"The safety of lutetium Lu 177 dotatate was rated 2 on the 1-3 scale since this is only a phase 2 trial, with some data indicating its safety but none confirming its efficacy."
Are there any opportunities for participation in this trial currently available?
"This clinical trial is still searching for participants, as evidenced by the listing on clinicaltrials.gov. It was first advertised on April 24th of 2023 and has since been revised on May 9th of the same year."
What is the current enrolment figure for this trial?
"Confirmed. Evidenced on clinicaltrials.gov, this research trial is presently recruiting participants and was posted to the platform on April 24th 2023 with a subsequent update made May 9th of the same year. A total of 25 patients are desired from 1 medical centre for enrolment in this study."
Share this study with friends
Copy Link
Messenger